The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model

M. W. Jennings, I. Boime, D. Daphna-Iken, A. Jablonka-Shariff, Alan J Conley, M. Colgin, L. A. Bidstrup, G. A. Meyers-Brown, T. R. Famula, J. F. Roser

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The efficacy of a recently engineered single chain recombinant equine follicle stimulating hormone (reFSH) was investigated in estrous cycling mares whose gonadotropins and follicular activity had been suppressed by concurrent treatment with progesterone and estradiol (P&E). Time of estrus was synchronized in 15 estrous cycling mares during the breeding season with prostaglandins F (PGF). The day after ovulation, mares were treated once daily with P&E for 14 days. Mares received a second injection of PGF on day 6 of the synchronized estrous cycle to induce luteolysis. On day 8 post-ovulation mares were randomly assigned to three groups: small dose reFSH-treatment group (0.5 mg reFSH IV, twice daily); large dose reFSH-treatment group (0.85 mg reFSH IV twice daily); control group (saline IV, twice daily). reFSH treatment occurred concurrently with the last week of P&E treatment. After a follicle or cohort of follicles reached 35 mm in diameter, mares were injected with 0.75 mg of recombinant equine luteinizing hormone (reLH) to induce ovulation. Post-treatment ovulation was assessed. Daily blood samples were collected for analysis of FSH, LH, estradiol, progesterone, and inhibin by radioimmunoassay (RIA). On the first day of reFSH/saline treatment, blood samples were collected periodically from 1 h prior to treatment to 6 h post-injection via an indwelling jugular catheter to determine acute changes in FSH concentrations. Monitoring of follicular activity, estrus, and ovulation was performed daily by utilizing a stallion and transrectal ultrasonography. A difference (p ≤ 0.05) between the largest diameter follicle in the reFSH-treatment groups compared to controls occurred on day 14 post-ovulation, the day treatments ended, and the difference continued until day 21 post-ovulation. reFSH-treatment groups had larger (p ≤ 0.05) numbers of 20-29 mm follicles (days 13-18), 30-34 mm follicles (days 15-20) and ≥35 mm follicles (days 16-21) than controls. Mares treated with reFSH, at either dose, took less time (average: 2.95 ± 0.42 days) to develop 2-3 times more pre-ovulatory follicles than control mares (7.8 ± 0.51 days) (p ≤ 0.05). The number of ovulations between treated mares and controls were similar due to a greater incidence of ovulation failure in reFSH-treated mares. During reFSH treatment, concentrations of plasma FSH, inhibin and estradiol were greater (p ≤ 0.05) compared to control concentrations. Plasma LH concentrations in reFSH-treated mares were suppressed and did not exhibit the ovulatory surge of controls (p ≤ 0.05). Plasma progesterone concentrations were not different across groups. These findings demonstrate the specific effects of reFSH to increase number of total follicles including pre-ovulatory follicles in mares with endogenous pituitary gonadotropins and follicular growth suppressed by a regimen of P&E.

Original languageEnglish (US)
Pages (from-to)291-307
Number of pages17
JournalAnimal Reproduction Science
Volume116
Issue number3-4
DOIs
StatePublished - Dec 2009

Fingerprint

follicle-stimulating hormone
Follicle Stimulating Hormone
mares
Horses
horses
Ovulation
ovulation
Growth
Therapeutics
Progesterone
estradiol
Estradiol
inhibin
progesterone
Inhibins
Dinoprost
Estrus
prostaglandins
estrus
dosage

Keywords

  • Follicles
  • Hormones
  • Mares
  • Ovulation
  • Recombinant equine FSH

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Food Animals
  • Endocrinology

Cite this

The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model. / Jennings, M. W.; Boime, I.; Daphna-Iken, D.; Jablonka-Shariff, A.; Conley, Alan J; Colgin, M.; Bidstrup, L. A.; Meyers-Brown, G. A.; Famula, T. R.; Roser, J. F.

In: Animal Reproduction Science, Vol. 116, No. 3-4, 12.2009, p. 291-307.

Research output: Contribution to journalArticle

Jennings, MW, Boime, I, Daphna-Iken, D, Jablonka-Shariff, A, Conley, AJ, Colgin, M, Bidstrup, LA, Meyers-Brown, GA, Famula, TR & Roser, JF 2009, 'The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model', Animal Reproduction Science, vol. 116, no. 3-4, pp. 291-307. https://doi.org/10.1016/j.anireprosci.2009.01.013
Jennings, M. W. ; Boime, I. ; Daphna-Iken, D. ; Jablonka-Shariff, A. ; Conley, Alan J ; Colgin, M. ; Bidstrup, L. A. ; Meyers-Brown, G. A. ; Famula, T. R. ; Roser, J. F. / The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model. In: Animal Reproduction Science. 2009 ; Vol. 116, No. 3-4. pp. 291-307.
@article{52790c960fc9420b94ed8a4722e20b2b,
title = "The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model",
abstract = "The efficacy of a recently engineered single chain recombinant equine follicle stimulating hormone (reFSH) was investigated in estrous cycling mares whose gonadotropins and follicular activity had been suppressed by concurrent treatment with progesterone and estradiol (P&E). Time of estrus was synchronized in 15 estrous cycling mares during the breeding season with prostaglandins F2α (PGF2α). The day after ovulation, mares were treated once daily with P&E for 14 days. Mares received a second injection of PGF2α on day 6 of the synchronized estrous cycle to induce luteolysis. On day 8 post-ovulation mares were randomly assigned to three groups: small dose reFSH-treatment group (0.5 mg reFSH IV, twice daily); large dose reFSH-treatment group (0.85 mg reFSH IV twice daily); control group (saline IV, twice daily). reFSH treatment occurred concurrently with the last week of P&E treatment. After a follicle or cohort of follicles reached 35 mm in diameter, mares were injected with 0.75 mg of recombinant equine luteinizing hormone (reLH) to induce ovulation. Post-treatment ovulation was assessed. Daily blood samples were collected for analysis of FSH, LH, estradiol, progesterone, and inhibin by radioimmunoassay (RIA). On the first day of reFSH/saline treatment, blood samples were collected periodically from 1 h prior to treatment to 6 h post-injection via an indwelling jugular catheter to determine acute changes in FSH concentrations. Monitoring of follicular activity, estrus, and ovulation was performed daily by utilizing a stallion and transrectal ultrasonography. A difference (p ≤ 0.05) between the largest diameter follicle in the reFSH-treatment groups compared to controls occurred on day 14 post-ovulation, the day treatments ended, and the difference continued until day 21 post-ovulation. reFSH-treatment groups had larger (p ≤ 0.05) numbers of 20-29 mm follicles (days 13-18), 30-34 mm follicles (days 15-20) and ≥35 mm follicles (days 16-21) than controls. Mares treated with reFSH, at either dose, took less time (average: 2.95 ± 0.42 days) to develop 2-3 times more pre-ovulatory follicles than control mares (7.8 ± 0.51 days) (p ≤ 0.05). The number of ovulations between treated mares and controls were similar due to a greater incidence of ovulation failure in reFSH-treated mares. During reFSH treatment, concentrations of plasma FSH, inhibin and estradiol were greater (p ≤ 0.05) compared to control concentrations. Plasma LH concentrations in reFSH-treated mares were suppressed and did not exhibit the ovulatory surge of controls (p ≤ 0.05). Plasma progesterone concentrations were not different across groups. These findings demonstrate the specific effects of reFSH to increase number of total follicles including pre-ovulatory follicles in mares with endogenous pituitary gonadotropins and follicular growth suppressed by a regimen of P&E.",
keywords = "Follicles, Hormones, Mares, Ovulation, Recombinant equine FSH",
author = "Jennings, {M. W.} and I. Boime and D. Daphna-Iken and A. Jablonka-Shariff and Conley, {Alan J} and M. Colgin and Bidstrup, {L. A.} and Meyers-Brown, {G. A.} and Famula, {T. R.} and Roser, {J. F.}",
year = "2009",
month = "12",
doi = "10.1016/j.anireprosci.2009.01.013",
language = "English (US)",
volume = "116",
pages = "291--307",
journal = "Animal Reproduction Science",
issn = "0378-4320",
publisher = "Elsevier",
number = "3-4",

}

TY - JOUR

T1 - The efficacy of recombinant equine follicle stimulating hormone (reFSH) to promote follicular growth in mares using a follicular suppression model

AU - Jennings, M. W.

AU - Boime, I.

AU - Daphna-Iken, D.

AU - Jablonka-Shariff, A.

AU - Conley, Alan J

AU - Colgin, M.

AU - Bidstrup, L. A.

AU - Meyers-Brown, G. A.

AU - Famula, T. R.

AU - Roser, J. F.

PY - 2009/12

Y1 - 2009/12

N2 - The efficacy of a recently engineered single chain recombinant equine follicle stimulating hormone (reFSH) was investigated in estrous cycling mares whose gonadotropins and follicular activity had been suppressed by concurrent treatment with progesterone and estradiol (P&E). Time of estrus was synchronized in 15 estrous cycling mares during the breeding season with prostaglandins F2α (PGF2α). The day after ovulation, mares were treated once daily with P&E for 14 days. Mares received a second injection of PGF2α on day 6 of the synchronized estrous cycle to induce luteolysis. On day 8 post-ovulation mares were randomly assigned to three groups: small dose reFSH-treatment group (0.5 mg reFSH IV, twice daily); large dose reFSH-treatment group (0.85 mg reFSH IV twice daily); control group (saline IV, twice daily). reFSH treatment occurred concurrently with the last week of P&E treatment. After a follicle or cohort of follicles reached 35 mm in diameter, mares were injected with 0.75 mg of recombinant equine luteinizing hormone (reLH) to induce ovulation. Post-treatment ovulation was assessed. Daily blood samples were collected for analysis of FSH, LH, estradiol, progesterone, and inhibin by radioimmunoassay (RIA). On the first day of reFSH/saline treatment, blood samples were collected periodically from 1 h prior to treatment to 6 h post-injection via an indwelling jugular catheter to determine acute changes in FSH concentrations. Monitoring of follicular activity, estrus, and ovulation was performed daily by utilizing a stallion and transrectal ultrasonography. A difference (p ≤ 0.05) between the largest diameter follicle in the reFSH-treatment groups compared to controls occurred on day 14 post-ovulation, the day treatments ended, and the difference continued until day 21 post-ovulation. reFSH-treatment groups had larger (p ≤ 0.05) numbers of 20-29 mm follicles (days 13-18), 30-34 mm follicles (days 15-20) and ≥35 mm follicles (days 16-21) than controls. Mares treated with reFSH, at either dose, took less time (average: 2.95 ± 0.42 days) to develop 2-3 times more pre-ovulatory follicles than control mares (7.8 ± 0.51 days) (p ≤ 0.05). The number of ovulations between treated mares and controls were similar due to a greater incidence of ovulation failure in reFSH-treated mares. During reFSH treatment, concentrations of plasma FSH, inhibin and estradiol were greater (p ≤ 0.05) compared to control concentrations. Plasma LH concentrations in reFSH-treated mares were suppressed and did not exhibit the ovulatory surge of controls (p ≤ 0.05). Plasma progesterone concentrations were not different across groups. These findings demonstrate the specific effects of reFSH to increase number of total follicles including pre-ovulatory follicles in mares with endogenous pituitary gonadotropins and follicular growth suppressed by a regimen of P&E.

AB - The efficacy of a recently engineered single chain recombinant equine follicle stimulating hormone (reFSH) was investigated in estrous cycling mares whose gonadotropins and follicular activity had been suppressed by concurrent treatment with progesterone and estradiol (P&E). Time of estrus was synchronized in 15 estrous cycling mares during the breeding season with prostaglandins F2α (PGF2α). The day after ovulation, mares were treated once daily with P&E for 14 days. Mares received a second injection of PGF2α on day 6 of the synchronized estrous cycle to induce luteolysis. On day 8 post-ovulation mares were randomly assigned to three groups: small dose reFSH-treatment group (0.5 mg reFSH IV, twice daily); large dose reFSH-treatment group (0.85 mg reFSH IV twice daily); control group (saline IV, twice daily). reFSH treatment occurred concurrently with the last week of P&E treatment. After a follicle or cohort of follicles reached 35 mm in diameter, mares were injected with 0.75 mg of recombinant equine luteinizing hormone (reLH) to induce ovulation. Post-treatment ovulation was assessed. Daily blood samples were collected for analysis of FSH, LH, estradiol, progesterone, and inhibin by radioimmunoassay (RIA). On the first day of reFSH/saline treatment, blood samples were collected periodically from 1 h prior to treatment to 6 h post-injection via an indwelling jugular catheter to determine acute changes in FSH concentrations. Monitoring of follicular activity, estrus, and ovulation was performed daily by utilizing a stallion and transrectal ultrasonography. A difference (p ≤ 0.05) between the largest diameter follicle in the reFSH-treatment groups compared to controls occurred on day 14 post-ovulation, the day treatments ended, and the difference continued until day 21 post-ovulation. reFSH-treatment groups had larger (p ≤ 0.05) numbers of 20-29 mm follicles (days 13-18), 30-34 mm follicles (days 15-20) and ≥35 mm follicles (days 16-21) than controls. Mares treated with reFSH, at either dose, took less time (average: 2.95 ± 0.42 days) to develop 2-3 times more pre-ovulatory follicles than control mares (7.8 ± 0.51 days) (p ≤ 0.05). The number of ovulations between treated mares and controls were similar due to a greater incidence of ovulation failure in reFSH-treated mares. During reFSH treatment, concentrations of plasma FSH, inhibin and estradiol were greater (p ≤ 0.05) compared to control concentrations. Plasma LH concentrations in reFSH-treated mares were suppressed and did not exhibit the ovulatory surge of controls (p ≤ 0.05). Plasma progesterone concentrations were not different across groups. These findings demonstrate the specific effects of reFSH to increase number of total follicles including pre-ovulatory follicles in mares with endogenous pituitary gonadotropins and follicular growth suppressed by a regimen of P&E.

KW - Follicles

KW - Hormones

KW - Mares

KW - Ovulation

KW - Recombinant equine FSH

UR - http://www.scopus.com/inward/record.url?scp=70350008105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350008105&partnerID=8YFLogxK

U2 - 10.1016/j.anireprosci.2009.01.013

DO - 10.1016/j.anireprosci.2009.01.013

M3 - Article

C2 - 19237253

AN - SCOPUS:70350008105

VL - 116

SP - 291

EP - 307

JO - Animal Reproduction Science

JF - Animal Reproduction Science

SN - 0378-4320

IS - 3-4

ER -